Prevention of Post-ERCP Pancreatitis by Intraduodenal Indomethacin in ERCP naïve patients

Not Applicable

Recruiting

• Conditions: Diseases of the digestive system

• Registration Number: KCT0002394
• Lead Sponsor: Chung-Ang Univerisity Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 926

Inclusion Criteria

1) Age = 20 or age = 80, 2) Patients with naïve papilla and first ERCP, 3) Diagnostic or therapeutic ERCP, 4) No evidence of significant abnormality in cardiopulmonary function, 5) No expectation of adverse event after indomethacin application.

Exclusion Criteria

1) Unwillingness or inability to informed consent for study, 2) Age < 20 or > 80, 3) Pregnant women, 4) Lactating women, 5) Clinical contraindication for ERCP, 6) History of allergy or hypersensitivity to aspirin or NSAIDs, 7) Recent history (within 7 days) of NSAIDs medication, 8) Serum creatinine > 1.4 mg/dL, 9) Active or recent (within 4 weeks) gastrointestinal bleeding, 10) Active cardiovascular or cerebrovascular disease, 11) Acute pancreatitis within 72 hours, 12) Chronic pancreatitis, 13) ERCP for stent removal or stent change, 14) Endoscopic sphicterotomy state, 15) Drug or alcohol abuser, 16) Psychiatric illness that anticipated inability to follow study protocol.

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified